Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597946975> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2597946975 abstract "TPS3109 Background: Ipilimumab is a monoclonal anti-CTLA-4 antibody that promotes T-cell activation and has been approved for the treatment of pts with advanced melanoma. The cytokine rIL-21 is a T-cell and NK-cell growth factor that has also demonstrated antitumor activity in selected solid tumors including MM. We hypothesize that coordinated stimulation of T and/or NK cell function with rIL-21 in conjunction with T-cell checkpoint inhibitor blockade with Ipi will achieve enhanced biologic and clinical activity compared to either agent alone. Here we describe an ongoing phase Ib study to investigate the clinical and biologic effects of combined treatment with rIL-21 and Ipi in pts with MM. Methods: The phase I study includes dose escalation (Part 1) using a 6 + 6 design and cohort expansion (Part 2). In Part 1 (n=48), successive cohorts of pts with melanoma will be treated with rIL-21 in combination with Ipi as follows: Arm A, rIL-21 (10, 30, or 50 μg/kg daily x 5) + Ipi (3 or 10 mg/kg Q3W) in a 3 week cycle; or Arm B, rIL-21 (30, 100, or 150 μg/kg weekly) + Ipi (3 or 10 mg/kg Q3W) in a 3 week cycle. In Part 1, all subjects will receive an initial cycle with rIL-21 monotherapy (lead-in) for biomarker and PK assessment that will be the same as the dose of rIL-21 specified for the cohort. Four cycles of combination treatment will follow the lead-in with restaging evaluation after 4 combination cycles. Subjects with initial benefit are eligible for retreatment at progression. In Part 2, pts (n=25/arm) will be randomly assigned to one of 3 cohorts: Ipi monotherapy at 3 mg/kg Q3W or Ipi + weekly rIL-21 or Ipi + daily rIL-21 at the MTD determined for each schedule in Part 1. The primary objectives of this study are to evaluate the safety of rIL-21 + Ipi and to define the MTD of the respective rIL-21 + Ipi regimens. Secondary objectives include assessment of the preliminary antitumor activity, pharmacokinetics, and immunogenicity. Exploratory objectives include investigation of the immunologic effects of this combination in peripheral blood and paired tumor biopsy specimens, and the association of these effects with clinical outcome. Clinical trial information: NCT01489059." @default.
- W2597946975 created "2017-04-07" @default.
- W2597946975 creator A5003873304 @default.
- W2597946975 creator A5008230245 @default.
- W2597946975 creator A5015793990 @default.
- W2597946975 creator A5021593027 @default.
- W2597946975 creator A5028479135 @default.
- W2597946975 creator A5029588412 @default.
- W2597946975 creator A5033798832 @default.
- W2597946975 creator A5034786338 @default.
- W2597946975 creator A5051746857 @default.
- W2597946975 creator A5052046806 @default.
- W2597946975 creator A5054535169 @default.
- W2597946975 creator A5063858836 @default.
- W2597946975 creator A5069690249 @default.
- W2597946975 creator A5072950627 @default.
- W2597946975 creator A5086165685 @default.
- W2597946975 date "2013-05-20" @default.
- W2597946975 modified "2023-10-01" @default.
- W2597946975 title "Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM)." @default.
- W2597946975 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.tps3109" @default.
- W2597946975 hasPublicationYear "2013" @default.
- W2597946975 type Work @default.
- W2597946975 sameAs 2597946975 @default.
- W2597946975 citedByCount "1" @default.
- W2597946975 countsByYear W25979469752014 @default.
- W2597946975 crossrefType "journal-article" @default.
- W2597946975 hasAuthorship W2597946975A5003873304 @default.
- W2597946975 hasAuthorship W2597946975A5008230245 @default.
- W2597946975 hasAuthorship W2597946975A5015793990 @default.
- W2597946975 hasAuthorship W2597946975A5021593027 @default.
- W2597946975 hasAuthorship W2597946975A5028479135 @default.
- W2597946975 hasAuthorship W2597946975A5029588412 @default.
- W2597946975 hasAuthorship W2597946975A5033798832 @default.
- W2597946975 hasAuthorship W2597946975A5034786338 @default.
- W2597946975 hasAuthorship W2597946975A5051746857 @default.
- W2597946975 hasAuthorship W2597946975A5052046806 @default.
- W2597946975 hasAuthorship W2597946975A5054535169 @default.
- W2597946975 hasAuthorship W2597946975A5063858836 @default.
- W2597946975 hasAuthorship W2597946975A5069690249 @default.
- W2597946975 hasAuthorship W2597946975A5072950627 @default.
- W2597946975 hasAuthorship W2597946975A5086165685 @default.
- W2597946975 hasConcept C121608353 @default.
- W2597946975 hasConcept C126322002 @default.
- W2597946975 hasConcept C143998085 @default.
- W2597946975 hasConcept C2776056953 @default.
- W2597946975 hasConcept C2777658100 @default.
- W2597946975 hasConcept C2777701055 @default.
- W2597946975 hasConcept C2781433595 @default.
- W2597946975 hasConcept C2994587330 @default.
- W2597946975 hasConcept C31760486 @default.
- W2597946975 hasConcept C502942594 @default.
- W2597946975 hasConcept C535046627 @default.
- W2597946975 hasConcept C71924100 @default.
- W2597946975 hasConceptScore W2597946975C121608353 @default.
- W2597946975 hasConceptScore W2597946975C126322002 @default.
- W2597946975 hasConceptScore W2597946975C143998085 @default.
- W2597946975 hasConceptScore W2597946975C2776056953 @default.
- W2597946975 hasConceptScore W2597946975C2777658100 @default.
- W2597946975 hasConceptScore W2597946975C2777701055 @default.
- W2597946975 hasConceptScore W2597946975C2781433595 @default.
- W2597946975 hasConceptScore W2597946975C2994587330 @default.
- W2597946975 hasConceptScore W2597946975C31760486 @default.
- W2597946975 hasConceptScore W2597946975C502942594 @default.
- W2597946975 hasConceptScore W2597946975C535046627 @default.
- W2597946975 hasConceptScore W2597946975C71924100 @default.
- W2597946975 hasLocation W25979469751 @default.
- W2597946975 hasOpenAccess W2597946975 @default.
- W2597946975 hasPrimaryLocation W25979469751 @default.
- W2597946975 hasRelatedWork W180009382 @default.
- W2597946975 hasRelatedWork W2157694919 @default.
- W2597946975 hasRelatedWork W2241396700 @default.
- W2597946975 hasRelatedWork W2243346685 @default.
- W2597946975 hasRelatedWork W2246004191 @default.
- W2597946975 hasRelatedWork W2325262739 @default.
- W2597946975 hasRelatedWork W2528032056 @default.
- W2597946975 hasRelatedWork W2528955564 @default.
- W2597946975 hasRelatedWork W2567294122 @default.
- W2597946975 hasRelatedWork W2588760906 @default.
- W2597946975 hasRelatedWork W2590161203 @default.
- W2597946975 hasRelatedWork W2595305902 @default.
- W2597946975 hasRelatedWork W2596109747 @default.
- W2597946975 hasRelatedWork W2600931526 @default.
- W2597946975 hasRelatedWork W2740235105 @default.
- W2597946975 hasRelatedWork W2802843211 @default.
- W2597946975 hasRelatedWork W2890295967 @default.
- W2597946975 hasRelatedWork W2892073983 @default.
- W2597946975 hasRelatedWork W2912271788 @default.
- W2597946975 hasRelatedWork W3031040149 @default.
- W2597946975 isParatext "false" @default.
- W2597946975 isRetracted "false" @default.
- W2597946975 magId "2597946975" @default.
- W2597946975 workType "article" @default.